Scilex Holding Company Other Comprehensive Income (Loss), Net of Tax
Scilex Holding Company (SCLX) reported Other Comprehensive Income (Loss), Net of Tax of -$432.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-14
- Scilex Holding Company other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$432.00K.
- Scilex Holding Company other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$747.00K.
- Scilex Holding Company other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$9.15M, a 800.61% decline year-over-year.
- Scilex Holding Company other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$2.97M, a 193.99% decline year-over-year.
- Scilex Holding Company other comprehensive income (loss), net of tax for fiscal 2025 was -$12.12M, a 291.86% decline from fiscal 2024.
- Scilex Holding Company other comprehensive income (loss), net of tax for fiscal 2024 was $6.32M.
- Scilex Holding Company other comprehensive income (loss), net of tax for fiscal 2023 was $0.00.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$432.00K 10-Q · filed 2026-08-14 | -$1.18M 10-Q · filed 2026-08-14 | -$10.33M derived: sum of 3 quarters · filed 2026-08-14 | -$13.30M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$747.00K 10-Q · filed 2026-08-14 | -$9.90M derived: sum of 2 quarters · filed 2026-08-14 | -$12.87M derived: sum of 3 quarters · filed 2026-08-14 | -$12.87M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$9.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$12.12M derived: sum of 2 quarters · filed 2026-04-10 | -$12.12M derived: sum of 3 quarters · filed 2026-08-14 | -$12.12M 10-K · filed 2026-04-10 | |||
| 2025-09-30 | -$2.97M 10-Q · filed 2025-11-14 | -$2.97M derived: sum of 2 quarters · filed 2026-08-14 | -$2.97M 10-Q · filed 2025-11-14 | -$1.66M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $1.31M derived: sum of 3 quarters · filed 2026-08-14 | $4.47M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-20 | $1.31M derived: sum of 2 quarters · filed 2026-05-20 | $4.47M derived: sum of 3 quarters · filed 2026-05-20 | $6.32M derived: sum of 4 quarters · filed 2026-05-20 | |||
| 2024-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $4.47M derived: sum of 2 quarters · filed 2026-04-10 | $6.32M derived: sum of 3 quarters · filed 2026-04-10 | $6.32M 10-K · filed 2026-04-10 | -$6.32M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $3.16M 10-Q · filed 2025-11-14 | -$3.16M 10-Q · filed 2025-01-17 | $5.01M derived: sum of 2 quarters · filed 2025-11-14 | $5.01M 10-Q · filed 2025-11-14 | -$5.01M 10-Q · filed 2025-01-17 | ||
| 2024-06-30 | $1.85M 10-Q · filed 2025-11-14 | -$1.85M 10-Q · filed 2024-08-13 | -$1.85M 10-Q · filed 2025-08-13 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $0.00 10-Q · filed 2025-01-17 | $0.00 derived: sum of 2 quarters · filed 2025-01-17 | $0.00 10-Q · filed 2025-01-17 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |